Am J Kidney Dis. 2007;50:239–47.PubMedCrossRef 4. Chang HY, Tung CW, Lee PH, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci. 2010;339:509–15.PubMed 5. Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids.
2011;30:1018–29.PubMedCrossRef 6. Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.PubMedCrossRef 7. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–7.PubMedCrossRef 8. Kodama S, Saito K, Yachi click here Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737–42.mTOR inhibitor PubMedCentralPubMedCrossRef 9. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18:526–30.PubMedCentralPubMedCrossRef 10. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease
through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.PubMedCrossRef 11. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 7-Cl-O-Nec1 cell line 2010;5:1388–93.PubMedCentralPubMedCrossRef 12. Collins AJ, Foley RN, Chavers B et al.
‘United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis. 2012; 59(1 Suppl 1):A7, e1–420. 13. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848–55.PubMedCrossRef 14. Okamoto K, Matsumoto K, Hille R, et al. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Beta adrenergic receptor kinase Natl Acad Sci USA. 2004;101:7931–6.PubMedCentralPubMedCrossRef 15. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthr Care Res (Hoboken). 2012;64:1431–46.CrossRef 16. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337–43.PubMed 17. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445–9.PubMedCrossRef 18. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.PubMedCrossRef 19. Dalbeth N, Kumar S, Stamp L, et al.